Search

Surgical challenges in advanced or recurrent thyroid malignancy

The management of thyroid malignancy and extent of surgery is controversial, especially considering the limitations of preoperative diagnosis. Neil Tolley provides guidance and reminds us of our responsibility not to over-treat. In the UK, 16% of thyroidectomies are performed for...

Management of olfactory dysfunction

An evidence-based update on olfactory dysfunction: who to image, how to test and what works – OT, CRS surgery, biologics and PRP. Olfactory dysfunction (OD) is highly prevalent, affecting more than 20% of the adult population with a clear age-related...

Otology training in low- and middle-income countries: a view from within

It is recognised that hearing loss and ear disease are far more common in less affluent parts of the world, and that those countries are often least able to provide treatment; so how can we prioritise care for these patients?...

Lancet Commission on Hearing Loss

The Lancet Commission on Hearing Loss was convened in 2019, and its main report will be published in 2023. We learn more about it here. The Lancet Commission on Hearing Loss was convened in 2019, and was charged by Richard...

Young ESPO’s thoughts about ESPO and the future of paediatric ORL

ESPO, and paediatric ORL in general, has a long tradition of encouraging our younger colleagues. This has led to innovative developments in clinical work, in research endeavours and in how paediatric ORL educational events are run. This article outlines some...

Jarrod Homer and Stuart Winter: Development of the sixth edition of the UK multidisciplinary head and neck cancer guidelines

Head and neck cancer care is a complex and constantly evolving field. What’s new and how are national guidelines on the subject produced? We spoke to Professors Homer and Winter, the lead authors of the most recent edition of the...

Hearing loss and Alport syndrome

Alport syndrome (AS) includes a group of hereditary diseases caused by mutations in the COL4A3, COL4A4 or COL4A5 genes. These genes are responsible for the biosynthesis of α3, α4 and α5 collagen IV chains, which are located in the glomerular...

The Veterans Hearing Fund

Dawn Bramham introduces us to the newly launched Veterans Hearing Fund (VHF). This organisation aims to improve the lives of military personnel with hearing loss by providing access to technologies, services and bespoke rehabilitation that are not routinely available via...

Platinum-based chemotherapy, tinnitus and hearing loss

Fortunately, the five-year survival rate of adult cancers is increasing. However, we are seeing for the first time the lasting effects of cancer treatments on people. As more people live with the long-term effects of treatment, such as chemotherapy, it is imperative to understand the impact it has on quality of life.

Aligning hearing and cognitive healthcare in older people

Published in print under the titleHearing care and dementia: professional insights on the new Lancet Commission findingsThe Lancet Commission on ‘Dementia prevention, intervention and care: 2024 report’ highlights a list of potential modifiable factors to reduce dementia risk. As with...